Mankind Pharma Ltd continued its downward trajectory, declining 0.47% to ₹2,412.2 as of 13:19 IST on the NSE, marking its fifth consecutive session of losses. According to reports from Business Standard, the stock was trading at this level during the trading session, reflecting sustained selling pressure in the pharmaceutical sector.
The stock's performance contrasted with broader market trends, as reported by Business Standard. While Mankind Pharma declined, the benchmark NIFTY was down 0.11% at 23,888.4, and the Sensex stood at 75,882.34, down 0.17%. The pharmaceutical sector showed mixed signals, with the Nifty Pharma index up 0.16% at 24,659.2. The June futures contract for the stock is quoting at ₹2,429.3, down 0.46% on the day, indicating continued bearish sentiment in the derivatives market.
Despite the recent decline, Mankind Pharma demonstrated resilience over longer timeframes, as reported by Business Standard. The stock gained 6.53% in the last one month, outperforming the Nifty Pharma index's 6.66% increase during the same period. This performance suggests the stock may be finding support levels despite the current selling pressure.
Trading volumes reflected reduced investor interest, according to Business Standard reports. The stock recorded 3.04 lakh shares in today's trading, significantly lower than the daily average of 7.96 lakh shares over the past month. The stock's PE ratio stands at 47.06 based on trailing twelve months earnings ending March 2026, indicating premium valuation in the pharmaceutical sector.
The stock's recent performance contrasted sharply with its annual results, as reported by Business Standard. Mankind Pharma tumbled 2.88% over the past year, significantly underperforming the NIFTY's 3.49% decline and the Nifty Pharma index's 15.46% surge. This divergence highlights the stock's sector-specific challenges despite the broader market's resilience.
